Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

PFE 31.25 -0.58 (-1.82%)
price chart
Pfizer Inc. Has AstraZeneca plc Or GlaxoSmithKline plc In Its Sights
Pfizer Inc., the world's largest pharmaceutical company, is struggling to find growth. Just like many of its peers, the company is suffering as sales of legacy drugs slide due to the loss of exclusive manufacturing rights.
Pfizer Inc. (PFE) Terminates $70 Million Deal With Repligen Corporation (RGEN)
Pfizer Inc. (NYSE:PFE) announced Friday its decision to terminate the $70 million collaboration deal with Repligen Corporation (NASDAQ:RGEN) for developing treatments for spinal muscular atrophy (SMA), returning some early stage treatments to Repligen.
Moving On From Pfizer's 2009 Dividend Cut
There's a lot to like about Pfizer (NYSE:PFE). For one, the company sports a 3.5% dividend yield, and growth in the payout is back after the firm cut the dividend to finance the Wyeth transaction back in 2009.
Pfizer to pay $400 million to avert investor class action trial
"This resolution reflects a desire by the company to avoid the distraction of continued litigation and focus on the needs of patients and physicians," said Christine Regan Lindenbloom, a Pfizer spokeswoman. Michael Dowd, a lawyer for the investors at ...
Pfizer Inc., Procter & Gamble Co Edge Out Earnings Estimates
Pfizer and Procter & Gamble released their latest quarter earnings reports before opening bell this morning. Pfizer posted adjusted earnings of 54 cents per share on $13.1 billion in revenue. Analysts had been expecting the drug maker to post earnings ...
Earnings: AT&T, Pfizer, Procter & Gamble, DuPont, Caterpillar, 3M ...  Richmond.com
Pfizer's $33 Billion Cash Pile Has Everyone Guessing
After the AstraZeneca deal fell apart, Pfizer approached Actavis Plc (ACT), people familiar with the matter said last year.
Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead
Pfizer Inc.'s (NYSE: PFE ) failed bid to acquire U.K.-based AstraZeneca (NYSE: AZN ) last year suggests that dealmakers are hard at work identifying new acquisition targets for the global drugmaker.
PFIZER INC (PFE) Earnings Report: Q4 2014 Conference Call Transcript
Good day, everyone, and welcome to Pfizer's Fourth-Quarter 2014 Earnings conference call. Today's call is being recorded.
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS ...  Business Wire (press release)
Will Pfizer Inc. (NYSE:PFE) Find Safe M&A Bets?
Ian Read, Pfizer Inc. (NYSE:PFE) CEO, said during a conference call with analysts that the drug maker is looking for deals that offer potential for creating value in near future.
Pfizer Inc. to Issue Quarterly Dividend of $0.28 on March 3rd (PFE)  Intercooler
Argus Raises Pfizer Price Target to $36.00 (PFE)  sleekmoney
Pfizer Inc. (NYSE:PFE) in Search of Different Takeover Options
Pfizer Inc. (NYSE:PFE) wants to improve its revenue growth and it is trying do so through acquisition. The first company it tried to acquire Teva Pharmaceutical Industries Ltd.